Jason Breaux
Known title: Chief Executive OfficerCIK: 0001640383
Jason Breaux's purchase track record
How the stock did after each of Jason Breaux's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 4 since November 23, 2021
Stock higher 6 months later
33%
3 months: 50%
Median 6-month return
-2.1%
3 months: +0.7%
Beat the S&P 500
67%
median +11.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/20/2026 | CCAP | $56K | -1.2% | pending | — |
| 5/12/2022 | CCAP | $48K | +4.3% | -12.4% | +0.7% |
| 3/1/2022 | CCAP | $44K | +2.1% | +3.9% | -7.4% |
| 11/23/2021 | CCAP | $46K | -0.8% | -2.1% | -16.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CCAP | ▲ Buy | Open Market | 5,000 | $56K | 5/20/2026 | View on chart |
| CCAP | ▼ Sell | Other | 6,044 | — | 12/4/2023 | View on chart |
| CCAP | ▲ Buy | Open Market | 2,800 | $48K | 5/12/2022 | View on chart |
| CCAP | ▲ Buy | Open Market | 2,500 | $44K | 3/1/2022 | View on chart |
| CCAP | ▼ Sell | Other | 4,398 | $0 | 12/9/2021 | View on chart |
| CCAP | ▲ Buy | Open Market | 2,500 | $46K | 11/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
CCAP: Coverage restored, fee cuts and rate hikes boost outlook
Crescent Capital BDC (CCAP) has seen its credit coverage restored after a recent downgrade, which is a positive sign for the company’s financial standing. The firm also announced fee reductions and benefited from higher interest rates, both of which can improve its income generation. These developments may support the stock’s price near its 18-touch support level of $10.77, although the market remains cautious.
CCAP: Coverage restored, fee cuts and rate hikes boost outlook. Crescent Capital BDC (CCAP) has seen its credit coverage restored after a recent downgrade, which is a positive sign for the company’s financial standing. The firm also announced fee reductions and benefited from higher interest rates, both of which can improve its income generation. These developments may support the stock’s price near its 18-touch support level of $10.77, although the market remains cautious.